Novan, Inc. NOVN
At closeJul 25, 2023, 4:00 PM EDT
52-week range unavailable
- Market cap
- 15.74M
- Revenue (ttm)
- 24.92M
- Profit margin
- -128.61%
- Shares out
- 28.02M
- Forward P/E
- -1.17
- Volume
- 6.93M
- Open
- 0.1368
- Previous close
- 0.0941
- Day's range
- 0.082 – 0.1395
- Beta
- -0.04
- Analysts
- Buy
- Price target
- 10.80 (+11377.2%)
- Earnings date
- Aug 10, 2023
3M -1.1140 (-95.21%)
Key statistics
- Enterprise value
- 40.21M
- PEG ratio
- 0.00
- Price / sales
- 0.63
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 64.20%
- Free cash flow
- -31.32M
- Total cash
- 12.54M
- Total debt
- 36.77M
- Return on equity
- -2098.89%
- Short % of float
- 1.62%
- 50-day average
- 0.89108
- 200-day average
- 1.20
Analyst view
Consensus: buy
- Target (low)
- 6.00
- Target (mean)
- 10.80
- Target (high)
- 17.00
- Strong buy0
- Buy2
- Hold1
- Sell0
- Strong sell0
Next earnings
Aug 10, 2023
Expected Aug 10, 2023. Consensus EPS estimate -0.20.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Aug 10, 2023 | Jun 1, 2023 | -0.09 | — | — | — |
| May 15, 2023 | Mar 1, 2023 | -0.32 | — | — | — |
| Mar 30, 2023 | Dec 1, 2022 | -0.31 | — | — | — |
| Nov 14, 2022 | Sep 1, 2022 | -0.39 | — | — | — |
| Aug 11, 2022 | Jun 1, 2022 | -0.59 | — | — | — |
| May 16, 2022 | Mar 1, 2022 | -0.57 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jun 1, 2023 | Oppenheimer | down | Outperform | Perform |
| May 16, 2023 | Oppenheimer | main | Outperform | Outperform |
| Mar 31, 2023 | Cantor Fitzgerald | reit | — | Overweight |
| Aug 16, 2022 | HC Wainwright & Co. | main | — | Buy |
| Jul 19, 2022 | Oppenheimer | init | — | Outperform |
| Sep 24, 2021 | HC Wainwright & Co. | main | — | Buy |
About Novan, Inc.
Novan, Inc., a medical dermatology company, focuses on developing and commercializing therapeutic products for skin diseases. Its clinical stage dermatology drug candidates include SB204, a topical monotherapy for the treatment of acne vulgaris; SB206, a topical anti-viral gel for the treatment of viral skin infections; SB208, a topical broad-spectrum anti-fungal gel for the treatment of fungal infections of the skin and nails, including athlete's foot and fungal nail infections; and SB414, a topical cream-based gel product candidate for the treatment of inflammatory skin diseases. The company develops SB207, an anti-viral product candidate for the treatment of external genital warts; WH602, a nitric oxide-containing intravaginal gel to treat high-risk human papilloma virus (HPV); WH504, a non-gel formulation product candidate to treat high-risk HPV; and SB019 for the treatment of SARS-CoV-2. Novan, Inc. has a license agreement with Sato Pharmaceutical Co., Ltd.; and a strategic alliance with Orion Corporation. The company was incorporated in 2006 and is headquartered in Durham, North Carolina.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- novan.com
News
Peanut Allergy Clinical Trial Pipeline: Insights into a Growing Landscape with 12+ Companies Advancing Novel Treatments| DelveInsight 
Novartis AGcompleted the acquisition of Regulus Therapeutics Inc.. 
12 Health Care Stocks Moving In Tuesday's Pre-Market Session 
Stocks That Hit 52-Week Lows On Friday 
Novan Enters into Agreement to Sell Substantially All of its Assets, including Berdazimer Gel, 10.3% (SB206), and Files for Chapter 11 Protection 
Why CorMedix Are Trading Lower By 22%; Here Are 20 Stocks Moving Premarket 
Benzinga's Top Ratings Upgrades, Downgrades For June 1, 2023 
Novan, Inc. (NOVN) Q1 2023 Earnings Call Transcript 
Earnings Scheduled For May 15, 2023 
Novan to Report First Quarter 2023 Financial Results on May 15, 2023
Your note
Sign in to keep a note on NOVN — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BIERMAN JAMES L | Director | Conversion of Exercise of derivative security | Jun 6, 2023 | 40,101 |
| GAY JOHN M. | Chief Financial Officer | Conversion of Exercise of derivative security | Jun 6, 2023 | 46,831 |
| GEER W KENT | Director | Conversion of Exercise of derivative security | Jun 6, 2023 | 37,683 |
| KEEGAN ROBERT J | Director | Conversion of Exercise of derivative security | Jun 6, 2023 | 42,404 |
| MALIN LIFE SCIENCES HOLDINGS, LTD. | Beneficial Owner of more than 10% of a Class of Security | Sale | Jul 1, 2019 | 0 |
| MARTIN G KELLY | Chief Executive Officer | Purchase | May 28, 2019 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Armistice Capital, LLC | 8.02% | 2,247,248 | 1.26M | Mar 30, 2023 |
| Vanguard Group, Inc. (The) | 2.88% | 807,993 | 453.85K | Mar 30, 2023 |
| Blackrock Inc. | 1.08% | 302,312 | 169.81K | Mar 30, 2023 |
| B. Riley Wealth Advisors, Inc. | 0.67% | 187,000 | 105.04K | Mar 30, 2023 |
| Geode Capital Management, LLC | 0.54% | 150,451 | 84.51K | Mar 30, 2023 |
| Renaissance Technologies, LLC | 0.30% | 85,374 | 47.95K | Mar 30, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.95% | 545,361 | 306.33K | Dec 30, 2022 |
| Vanguard Extended Market Index Fund | 0.75% | 210,175 | 118.06K | Dec 30, 2022 |
| Fidelity Extended Market Index Fund | 0.29% | 81,805 | 45.95K | Feb 27, 2023 |
| iShares Micro Cap ETF | 0.15% | 41,291 | 23.19K | Feb 27, 2023 |
| Fidelity Series Total Market Index Fund | 0.10% | 27,734 | 15.58K | Feb 27, 2023 |
| Fidelity Total Market Index Fund | 0.07% | 20,460 | 11.49K | Feb 27, 2023 |